Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Estimates and Forecast Timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. GVR’s Internal Database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.5. Information Analysis
1.5.1. Data Analysis Models
1.6. Market Formulation & Data Visualization
1.7. Model Details
1.7.1. Commodity Flow Analysis
1.8. List of Secondary Sources
1.9. Objectives
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Global Trastuzumab deruxtecan (Enhertu) Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
3.3.3. Pipeline Analysis
3.3.4. Pricing Analysis
Chapter 4. Global Trastuzumab deruxtecan (Enhertu) Market: Regional Estimates & Trend Analysis
4.1. Regional Market Share Analysis, 2024 & 2033
4.2. Regional Market Dashboard
4.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
4.4. North America
4.5. Europe
4.6. Asia Pacific
4.7. Latin America
4.8. Middle East and Africa
Chapter 5. Competitive Landscape
5.1. Company Profile
5.1.1. Daiichi Sankyo Company, Limited.
5.1.1.1. Overview
5.1.1.2. Financial Performance
5.1.1.3. Strategic Mapping
5.1.2. AstraZeneca
5.1.2.1. Overview
5.1.2.2. Financial Performance
5.1.2.3. Strategic Mapping
5.2. Concurrent Competitive Landscape
5.2.1. Pfizer Inc.
5.2.1.1. Overview
5.2.1.2. Financial Performance
5.2.1.3. Product Benchmarking
5.2.1.4. Strategic Mapping
5.2.2. Roche Holding AG
5.2.2.1. Overview
5.2.2.2. Financial Performance
5.2.2.3. Product Benchmarking
5.2.2.4. Strategic Mapping
5.2.3. Novartis AG
5.2.3.1. Overview
5.2.3.2. Financial Performance
5.2.3.3. Product Benchmarking
5.2.3.4. Strategic Mapping
5.2.4. Johnson & Johnson (Janssen Pharmaceuticals)
5.2.4.1. Overview
5.2.4.2. Financial Performance
5.2.4.3. Product Benchmarking
5.2.4.4. Strategic Mapping
5.2.5. Merck & Co., Inc.
5.2.5.1. Overview
5.2.5.2. Financial Performance
5.2.5.3. Product Benchmarking
5.2.5.4. Strategic Mapping
List of Tables
Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 Global Trastuzumab deruxtecan (Enhertu) market, by region, 2021 - 2033 (USD Million)
List of Figures
Fig. 1 Trastuzumab deruxtecan (Enhertu) market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 Market formulation & validation
Fig. 8 Market snapshot
Fig. 9 Indication outlook (USD Million)
Fig. 10 Competitive landscape
Fig. 11 Trastuzumab deruxtecan (Enhertu) market dynamics
Fig. 12 Trastuzumab deruxtecan (Enhertu) market: Porter’s five forces analysis
Fig. 13 Trastuzumab deruxtecan (Enhertu) market: PESTLE analysis
Fig. 14 Trastuzumab deruxtecan (Enhertu) market revenue, by region
Fig. 15 Regional marketplace: Key takeaways
Fig. 16 North America Trastuzumab deruxtecan (Enhertu) market, 2021 - 2033 (USD Million)
Fig. 17 Europe Trastuzumab deruxtecan (Enhertu) market, 2021 - 2033 (USD Million)
Fig. 18 Asia Pacific Trastuzumab deruxtecan (Enhertu) market, 2021 - 2033 (USD Million)
Fig. 19 Latin America Trastuzumab deruxtecan (Enhertu) market, 2021 - 2033 (USD Million)
Fig. 20 MEA Trastuzumab deruxtecan (Enhertu) market, 2021 - 2033 (USD Million)
Fig. 21 Company categorization
Fig. 22 Company market position analysis
Fig. 23 Strategic framework
Trusted market insights - try a free sample
See how our reports are structured and why industry leaders rely on Grand View Research. Get a free sample or ask us to tailor this report to your needs.
